Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04834102
  4. Details
NCT04834102 Clinical Trial

COVID-19 Induced Telogen Effluvium

Covid19 Clinical Trial

Official title:
COVID-19 Induced Telogen Effluvium

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04834102
Other study ID # 2021/0123
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 27, 2021
Est. completion date April 27, 2021

Study information
Verified date April 2021
Source Istanbul Medeniyet University
Contact Umut Mert YILDIRIM, Dr.
Phone +905423383842
Email umutmertyildirim@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Description:

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date April 27, 2021
Est. primary completion date April 27, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sars-CoV-2 infection in the past year Exclusion Criteria: - Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Blood Tests
Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity

Locations
Country Name City State
Turkey Istanbul Medeniyet University Istanbul Kadiköy

Sponsors (1)
Lead Sponsor Collaborator
Istanbul Medeniyet University

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320. Review. — View Citation

Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol. 2021 Mar;84(3):773-775. doi: 10.1016/j.jaad.2020.11.032. Epub 2020 Dec 10. — View Citation

Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23. — View Citation

Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S, Offidani A. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan;34(1):e14547. doi: 10. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Hair shedding Physical examination of hair and scalp, trichoscopy, hair pull test 3 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3